Monday’s Cabinet Economic Coordination Committee (ECC) approved maximum retail prices of four new cardiac stents from Rs. 53,130 to Rs. 72,450.
Senator Ishaq Dar chaired the ECC. The committee approved the Ministry of National Health Services, Regulations, and Coordination’s report of the National Price Fixation Committee’s maximum retail prices for four innovative cardiac stents.
The ministry proposed retail prices of Rs. 58,765 for Promus Premier, 65,507 for Sirokimus Eluting Coronary, 72,450 for Novolimus Drug, and 53,130 for Cre8 Amphilimus.
The meeting was informed that the Supreme Court Order dated March 20, 2018, and subsequent order dated January 10, 2020, passed in Human Right Case, established a National Price Fixation Committee for life-saving medical devices and notified its terms of reference (TORs) on September 8, 2020, with federal government approval.
S.R.0.1559 from August 18, 2022 describes how to fix and review cardiac stent MRPs. The committee approved MRPs (base prices) for four cardiac stent classifications on February 21, 2023.